National Institute on Drug Abuse; Notice of Closed Meetings, 46252-46253 [2017-21265]
Download as PDF
46252
Federal Register / Vol. 82, No. 191 / Wednesday, October 4, 2017 / Notices
any institution employing her shall
submit, in conjunction with each
application for PHS funds, or report,
manuscript, or abstract involving PHSsupported research in which
Respondent is involved, a certification
to ORI that the data provided by
Respondent are based on actual
experiments or are otherwise
legitimately derived and that the data,
procedures, and methodology are
accurately reported in the application,
report, manuscript, or abstract;
(3) to exclude herself voluntarily from
serving in any advisory capacity to PHS
including, but not limited to, service on
any PHS advisory committee, board,
and/or peer review committee, or as a
consultant for a period of three (3) years,
beginning with the effective date of the
Agreement; and
(4) that as a condition of the
Agreement, Respondent will request
that PLoS One 8(8):e71868, 2013 be
corrected or retracted.
FOR FURTHER INFORMATION CONTACT:
Director, Office of Research Integrity,
1101 Wootton Parkway, Suite 750,
Rockville, MD 20852, (240) 453–8200.
Kathryn M. Partin,
Director, Office of Research Integrity.
[FR Doc. 2017–21367 Filed 10–3–17; 8:45 am]
BILLING CODE 4150–31–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Human Genome Research
Institute; Notice of Closed Meeting
sradovich on DSK3GMQ082PROD with NOTICES
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Human
Genome Research Institute Special Emphasis
Panel, SEP U24 Research Resource.
Date: November 30, 2017.
Time: 11:00 a.m. to 2:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Human Genome Research
Institute, 5635 Fishers Lane, Suite 3146,
VerDate Sep<11>2014
20:18 Oct 03, 2017
Jkt 244001
Rockville, MD 20852 (Telephone Conference
Call).
Contact Person: Rudy O. Pozzatti, Ph.D.,
Scientific Review Officer, Scientific Review
Branch, National Human Genome Research
Institute, 5635 Fishers Lane, Suite 4076, MSC
9306, Rockville, MD 20852, (301) 402–0838,
pozzattr@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.172, Human Genome
Research, National Institutes of Health, HHS)
Dated: September 28, 2017.
Sylvia L. Neal,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2017–21263 Filed 10–3–17; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute on Drug Abuse;
Notice of Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel; Multisite Clinical Trials.
Date: October 19, 2017.
Time: 1:00 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Neuroscience Center, 6001 Executive
Boulevard, Rockville, MD 20852, (Telephone
Conference Call).
Contact Person: Shang-Yi Anne Tsai,
Ph.D., Scientific Review Officer, Office of
Extramural Policy and Review, Division of
Extramural Research, National Institute on
Drug Abuse, NIH, DHHS, 6001 Executive
Boulevard, Room 4228, MSC 9550, Bethesda,
MD 20892, 301–827–5842, shangyi.tsai@
nih.gov.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel; NIDA
Mentored Clinical Scientists Development
Program Award in Drug Abuse and
Addiction (K12).
Date: October 25, 2017.
Time: 9:00 a.m. to 12:00 p.m.
Agenda: To review and evaluate grant
applications.
PO 00000
Frm 00042
Fmt 4703
Sfmt 4703
Place: National Institutes of Health,
Neuroscience Center, 6001 Executive
Boulevard, Rockville, MD 20852.
Contact Person: Susan O. McGuire, Ph.D.,
Scientific Review Officer, Office of
Extramural Policy and Review, National
Institute on Drug Abuse, National Institutes
of Health, DHHS, 6001 Executive Blvd.,
Room 4245, Rockville, MD 20852, (301) 827–
5817, mcguireso@mail.nih.gov.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel; NIH
Pathway to Independence Award (K99/R00).
Date: October 25, 2017.
Time: 1:00 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Neuroscience Center, 6001 Executive
Boulevard, Rockville, MD 20852.
Contact Person: Susan O. McGuire, Ph.D.,
Scientific Review Officer, Office of
Extramural Policy and Review, National
Institute on Drug Abuse, National Institutes
of Health, DHHS, 6001 Executive Blvd.,
Room 4245, Rockville, MD 20852, (301) 827–
5817, mcguireso@mail.nih.gov.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel; (T32)
Ruth L. Kirschstein National Research
Service Award (NRSA) Institutional Research
Training Grants.
Date: October 26–27, 2017.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Neuroscience Center, 6001 Executive
Boulevard, Rockville, MD 20852.
Contact Person: Susan O. McGuire, Ph.D.
Scientific Review Officer, Office of
Extramural Policy and Review, National
Institute on Drug Abuse, National Institutes
of Health, DHHS, 6001 Executive Blvd.,
Room 4245, Rockville, MD 20852, (301) 827–
5817, mcguireso@mail.nih.gov.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel;
Exploring Novel RNA Modifications in HIV/
AIDS and Substance Use Disorders (R01,
R21).
Date: November 1, 2017.
Time: 9:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Neuroscience Center, 6001 Executive
Boulevard, Rockville, MD 20852,
Contact Person: Susan O. McGuire, Ph.D.,
Scientific Review Officer, Office of
Extramural Policy and Review, National
Institute on Drug Abuse, National Institutes
of Health, DHHS, 6001 Executive Blvd.,
Room 4245, Rockville, MD 20852, (301) 827–
5817, mcguireso@mail.nih.gov.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel; CuttingEdge Basic Research Awards (CEBRA) (R21).
Date: November 29, 2017.
Time: 9:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Bethesda North Marriott Hotel &
Conference Center, 5701 Marinelli Road,
Bethesda, MD 20852.
E:\FR\FM\04OCN1.SGM
04OCN1
Federal Register / Vol. 82, No. 191 / Wednesday, October 4, 2017 / Notices
Contact Person: Shang-Yi Anne Tsai,
Ph.D., Scientific Review Officer, Office of
Extramural Policy and Review, Division of
Extramural Research, National Institute on
Drug Abuse, NIH, DHHS, 6001 Executive
Boulevard, Room 4228, MSC 9550, Bethesda,
MD 20892, 301–827–5842, shangyi.tsai@
nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos.: 93.279, Drug Abuse and
Addiction Research Programs, National
Institutes of Health, HHS)
Dated: September 28, 2017.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory
Committee Policy.
Dated: September 28, 2017.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory
Committee Policy.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
[FR Doc. 2017–21264 Filed 10–3–17; 8:45 am]
Submission for OMB Review; 30-Day
Comment Request, The National
Institute of Mental Health Data Archive
(NDA), National Institute of Mental
Health
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meeting
sradovich on DSK3GMQ082PROD with NOTICES
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of a
meeting of Microbiology, Infectious
Diseases and AIDS Initial Review Group
Microbiology and Infectious Diseases
Research Committee.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Microbiology,
Infectious Diseases and AIDS Initial Review
Group; Microbiology and Infectious Diseases
Research Committee.
Date: October 30–31, 2017.
Time: 12:00 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 5601
Fishers Lane, Rockville, MD 20892 (Virtual
Meeting).
Contact Person: Frank S. De Silva, Ph.D.,
Scientific Review Officer, Scientific Review
Program, Division of Extramural Activities,
Room #3E72A, National Institutes of Health/
NIAID, 5601 Fishers Lane, MSC 9834,
Bethesda, MD 20892934, (240) 669–5023,
fdesilva@niaid.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
VerDate Sep<11>2014
20:18 Oct 03, 2017
Jkt 244001
National Institutes of Health
National Institutes of Health.
Notice.
AGENCY:
National Institutes of Health
ACTION:
National Institute on Drug Abuse;
Notice of Closed Meeting
SUMMARY:
[FR Doc. 2017–21265 Filed 10–3–17; 8:45 am]
BILLING CODE 4140–01–P
46253
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting of the Board of
Scientific Counselors, NIDA.
The meeting will be closed to the
public as indicated below in accordance
with the provisions set forth in section
552b(c)(6), Title 5 U.S.C., as amended
for the review, discussion, and
evaluation of individual intramural
programs and projects conducted by the
National Institute on Drug Abuse,
including consideration of personnel
qualifications and performance, and the
competence of individual investigators,
the disclosure of which would
constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Board of Scientific
Counselors, NIDA.
Date: November 7, 2017.
Closed: 8:00 a.m. to 4:30 p.m.
Agenda: To review and evaluate personal
qualifications and performance, and
competence of individual investigators.
Place: Intramural Research Program,
National Institute on Drug Abuse, NIH, Johns
Hopkins Bayview Campus, Baltimore, MD
21223.
Contact Person: Joshua Kysiak, Program
Specialist, Biomedical Research Center,
Intramural Research Program, National
Institute on Drug Abuse, NIH, DHHS, 251
Bayview Boulevard, Baltimore, MD 21224,
443–740–2465, kysiakjo@nida.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos.: 93.279, Drug Abuse and
Addiction Research Programs, National
Institutes of Health, HHS)
Dated: September 28, 2017.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2017–21266 Filed 10–3–17; 8:45 am]
BILLING CODE 4140–01–P
PO 00000
Frm 00043
Fmt 4703
Sfmt 4703
In compliance with the
Paperwork Reduction Act of 1995, the
National Institutes of Health (NIH) has
submitted to the Office of Management
and Budget (OMB) a request for review
and approval of the information
collection listed below. This proposed
information collection was previously
published in the Federal Register on
July 11, 2017, and allowed 60 days for
public comment. No public comments
were received. The purpose of this
notice is to allow an additional 30 days
for public comment.
DATES: Comments regarding this
information collection are best assured
of having their full effect if received
within 30-days of the date of this
publication.
Written comments and/or
suggestions regarding the item(s)
contained in this notice, especially
regarding the estimated public burden
and associated response time, should be
directed to the: Office of Management
and Budget, Office of Regulatory Affairs,
OIRA_submission@omb.eop.gov or by
fax to 202–395–6974, Attention: Desk
Officer for NIH.
FOR FURTHER INFORMATION CONTACT: To
request more information on the
proposed project or to obtain a copy of
the data collection plans and
instruments, contact: Melba Rojas,
NIMH Project Clearance Liaison,
Science Policy and Evaluation Branch,
Office of Science Policy, Planning and
Communications, NIMH, Neuroscience
Center, 6001 Executive Boulevard, MSC
9667, Bethesda, Maryland 20892, call
301–443–4335, or email your request,
including your mailing address, to
nimhprapubliccomments@mail.nih.gov.
Formal requests for additional plans and
instruments must be requested in
writing.
ADDRESSES:
The
National Institute of Mental Health
(NIMH), National Institutes of Health,
may not conduct or sponsor, and the
respondent is not required to respond
to, an information collection that has
been extended, revised, or implemented
on or after October 1, 1995, unless it
SUPPLEMENTARY INFORMATION:
E:\FR\FM\04OCN1.SGM
04OCN1
Agencies
[Federal Register Volume 82, Number 191 (Wednesday, October 4, 2017)]
[Notices]
[Pages 46252-46253]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-21265]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute on Drug Abuse; Notice of Closed Meetings
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meetings.
The meetings will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Institute on Drug Abuse Special
Emphasis Panel; Multi-site Clinical Trials.
Date: October 19, 2017.
Time: 1:00 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Neuroscience Center, 6001
Executive Boulevard, Rockville, MD 20852, (Telephone Conference
Call).
Contact Person: Shang-Yi Anne Tsai, Ph.D., Scientific Review
Officer, Office of Extramural Policy and Review, Division of
Extramural Research, National Institute on Drug Abuse, NIH, DHHS,
6001 Executive Boulevard, Room 4228, MSC 9550, Bethesda, MD 20892,
301-827-5842, shangyi.tsai@nih.gov.
Name of Committee: National Institute on Drug Abuse Special
Emphasis Panel; NIDA Mentored Clinical Scientists Development
Program Award in Drug Abuse and Addiction (K12).
Date: October 25, 2017.
Time: 9:00 a.m. to 12:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Neuroscience Center, 6001
Executive Boulevard, Rockville, MD 20852.
Contact Person: Susan O. McGuire, Ph.D., Scientific Review
Officer, Office of Extramural Policy and Review, National Institute
on Drug Abuse, National Institutes of Health, DHHS, 6001 Executive
Blvd., Room 4245, Rockville, MD 20852, (301) 827-5817,
mcguireso@mail.nih.gov.
Name of Committee: National Institute on Drug Abuse Special
Emphasis Panel; NIH Pathway to Independence Award (K99/R00).
Date: October 25, 2017.
Time: 1:00 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Neuroscience Center, 6001
Executive Boulevard, Rockville, MD 20852.
Contact Person: Susan O. McGuire, Ph.D., Scientific Review
Officer, Office of Extramural Policy and Review, National Institute
on Drug Abuse, National Institutes of Health, DHHS, 6001 Executive
Blvd., Room 4245, Rockville, MD 20852, (301) 827-5817,
mcguireso@mail.nih.gov.
Name of Committee: National Institute on Drug Abuse Special
Emphasis Panel; (T32) Ruth L. Kirschstein National Research Service
Award (NRSA) Institutional Research Training Grants.
Date: October 26-27, 2017.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Neuroscience Center, 6001
Executive Boulevard, Rockville, MD 20852.
Contact Person: Susan O. McGuire, Ph.D. Scientific Review
Officer, Office of Extramural Policy and Review, National Institute
on Drug Abuse, National Institutes of Health, DHHS, 6001 Executive
Blvd., Room 4245, Rockville, MD 20852, (301) 827-5817,
mcguireso@mail.nih.gov.
Name of Committee: National Institute on Drug Abuse Special
Emphasis Panel; Exploring Novel RNA Modifications in HIV/AIDS and
Substance Use Disorders (R01, R21).
Date: November 1, 2017.
Time: 9:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Neuroscience Center, 6001
Executive Boulevard, Rockville, MD 20852,
Contact Person: Susan O. McGuire, Ph.D., Scientific Review
Officer, Office of Extramural Policy and Review, National Institute
on Drug Abuse, National Institutes of Health, DHHS, 6001 Executive
Blvd., Room 4245, Rockville, MD 20852, (301) 827-5817,
mcguireso@mail.nih.gov.
Name of Committee: National Institute on Drug Abuse Special
Emphasis Panel; Cutting-Edge Basic Research Awards (CEBRA) (R21).
Date: November 29, 2017.
Time: 9:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant applications.
Place: Bethesda North Marriott Hotel & Conference Center, 5701
Marinelli Road, Bethesda, MD 20852.
[[Page 46253]]
Contact Person: Shang-Yi Anne Tsai, Ph.D., Scientific Review
Officer, Office of Extramural Policy and Review, Division of
Extramural Research, National Institute on Drug Abuse, NIH, DHHS,
6001 Executive Boulevard, Room 4228, MSC 9550, Bethesda, MD 20892,
301-827-5842, shangyi.tsai@nih.gov.
(Catalogue of Federal Domestic Assistance Program Nos.: 93.279, Drug
Abuse and Addiction Research Programs, National Institutes of
Health, HHS)
Dated: September 28, 2017.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2017-21265 Filed 10-3-17; 8:45 am]
BILLING CODE 4140-01-P